NewMarket Corporation has announced an increase in its quarterly dividend, raising it from $3.00 to $3.25 per share. This decision, made by the company’s Board of Directors, marks an approximate 8% increase. The new dividend reflects the company's ongoing commitment to returning value to its shareholders.
The quarterly dividend is equivalent to an annual dividend of $13.00 per share, up from $12.00 per share. This adjustment indicates a positive outlook for NewMarket as it continues to perform well in the industrial organic chemicals sector.
Background
NewMarket Corporation, traded under the ticker symbol NEU on the New York Stock Exchange, operates in the industrial organic chemicals sector (SIC: 2860). The company is based in Richmond, Virginia, and has a long history of providing chemical solutions through its subsidiaries, including Afton Chemical Corporation and Ethyl Corporation. Recent filings include a 10-Q on October 29, 2026, and an 8-K on the same day reporting the dividend increase.
What the Filing Says
According to the filing, "The Company’s Board of Directors had approved raising the quarterly dividend approximately 8% from $3.00 per share on the common stock of the Company to $3.25 per share." The dividend is payable on January 1, 2027, to shareholders of record as of December 15, 2026.
Impact
This increase in dividend may positively affect shareholders, as it demonstrates the company’s financial health and commitment to returning profits to investors. The decision may also influence other companies within the industrial organic chemicals sector to consider similar increases in their dividends as they compete for investor interest.
What's Next
The filing does not say what happens next, but future dividends will be subject to quarterly determination and declaration by the Board of Directors.
Read Next
Westlake BioPartners Discloses Major Stake in Latigo Biotherapeutics
Westlake BioPartners Acquires Significant Stake in Electra Therapeutics
Coletti Reports New Stock Transactions for Cintas Corp
Bain Capital Life Sciences acquires 9.99% stake in ADC Therapeutics
Studio City International Holdings reports major share transactions
Saba Capital Management acquires shares in New Germany Fund






